Por: RTTNews Health September 29, 2023
AbbVie () announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments.The data did not demonstrate that the treatment combination significantly improved progression-free survival (PFS), the primary endpoint of the... + full article
Politico USA Health September 30, 2023
A federal judge on Friday denied business groups’ move to halt Medicare’s new drug price negotiation program while multiple lawsuits challenging its constitutionality wind through the courts. The decision by Judge Michael J. Newman, a Trump appointee, in Ohio’s Southern... + más
Why do so many older adults choose Medicare Advantage? | ABC News
Why do so many older adults choose Medicare Advantage? | Associated Press
RTTNews USA Health August 28, 2023
Biopharmaceutical company AbbVie, Inc. () announced Monday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for risankizumab (SKYRIZI, 1200 mg intravenous [IV] [induction dose] as well as... + más
High school scores and top performers from Thursday, March 9 | Orlando Sentinel
High school scores and top performers from Friday, March 24 | Orlando Sentinel
MarketWatch USA Business February 09, 2023
International sales of Humira fell 26.5% from last year as the company lost patent protection in Europe and . However, revenue for the drug that treats Crohn’s disease grew 4.6% globally in the quarter to $5.58 billion, which was slightly above analysts’ estimates. said... + más
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System | The New York Times
Cigna’s PBM Express Scripts Latest To Put Less Pricey Biosimilars Of Abbvie’s Humira On Preferred Drug List | Forbes
The New York Times USA Business January 28, 2023
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug,... + más
Will More Women Patent Attorneys Lead To More Women Inventors? | Forbes
Samsung Beats IBM, Apple, Intel, Google For 2022 Patent Crown; 56% Of U.S. Patents Go To Foreign Firms | Forbes
Forbes USA Tech December 05, 2022
Cigna’s pharmacy benefit manager Express Scripts will put “multiple biosimilar versions of Abbvie’s ... [+] expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a formulary in 2023. AbbVie's signature drug Humira is... + más
Cigna received millions of Medicare dollars based on invalid diagnoses, lawsuit claims | ABC News
How To Get Away With Corporate Murder: Unbundling And Disrupting Pharmacy Benefit Managers (Part 2) | Forbes
RTTNews USA Health October 28, 2022
AbbVie () announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory... + más
Don’t Pay for Cord-Blood Banking | The Atlantic
Prime Video’s Aparna Purohit Reveals How Madhuri Dixit Got Onboard For ‘Maja Ma’ | Forbes
9to5Mac USA Tech October 03, 2022
After launching in 2019, to help organizations manage their Apple fleet, Kandji went to work on solving additional problems. Today, announced its new Device Harmony platform, which is aimed at bridging the gap between and InfoSec teams, so they can truly work together to keep... + más
Logitech finally makes a wireless mechanical keyboard with a true Mac layout | Ars Technica
What are all the solutions needed to run a fleet of Macs at Work? | 9to5Mac
About iurex | Privacy Policy | Disclaimer |